Xenon Pharmaceuticals
XENE
206 hedge funds and large institutions have $2.58B invested in Xenon Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 69 increasing their positions, 73 reducing their positions, and 23 closing their positions.
114% more call options, than puts
Call options by funds: $14.8M | Put options by funds: $6.93M
8% more funds holding in top 10
Funds holding in top 10: 13 → 14 (+1)
0.14% more ownership
Funds ownership: 100.08% → 100.23% (+0.14%)
5% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 73
1% less funds holding
Funds holding: 209 → 206 (-3)
13% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 23
14% less capital invested
Capital invested by funds: $2.99B → $2.58B (-$415M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$31.5M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$28.9M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$24.7M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$20.6M |
| 5 |
VPC
Vestal Point Capital
New York
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$24.5M |
| 2 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$24.3M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
-$20.2M |
| 4 |
CC
Commodore Capital
New York
|
-$15.8M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$12.4M |
XENE Hedge Fund Activity: Q1 2025 in Review
206 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Xenon Pharmaceuticals (XENE) for Q1 2025, worth a combined $2.58B — down 14% from $2.99B a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of XENE and 20 opened new positions — a net loss of 3 holders — while 73 trimmed existing stakes and 69 added.
The largest buyer was Deep Track Capital, adding an estimated $31.5M. The largest seller was Baker Bros. Advisors, cutting an estimated $24.5M.
- 206 institutional investors held Xenon Pharmaceuticals (XENE) as of Q1 2025, down from 209 in Q4 2024.
- Funds reported $2.58B of Xenon Pharmaceuticals stock for Q1 2025, down 14% quarter-over-quarter.
- 20 funds opened new Xenon Pharmaceuticals positions in Q1 2025 and 23 closed out, a net change of -3 holders.
- The largest Xenon Pharmaceuticals buyer in Q1 2025 was Deep Track Capital, an estimated $31.5M added.
- The largest Xenon Pharmaceuticals seller in Q1 2025 was Baker Bros. Advisors, an estimated $24.5M sold.
Based on aggregated 13F filings for Q1 2025.